🧬 This Week in Gene & Cell Therapy: Klotho’s Gene Therapy Deal, Sarepta’s FDA Challenge, NKGen Approval and More
From a new partnership aiming to accelerate gene therapy manufacturing to groundbreaking FDA approvals for neurodegenerative treatments, this week’s episode covers the most significant updates in the world of gene and cell therapy. Whether you’re tracking CAR-T advancements, regulatory news, or new therapeutic partnerships, we’ve got you covered with the latest milestones shaping the future of biotech. 🔬💡
🔍 Highlights in this episode:
💥 Klotho Neurosciences Partners with AAVnerGene for Gene Therapy Manufacturing
🏅 Sarepta Defies FDA Request to Halt Elevidys Shipments Amid Safety Concerns
🤔 Dispatch Bio Secures $216 Million to Target Solid Tumors with Immune System
🇺🇸 Senti Bio to Present CAR-NK Cell Therapy at BioScience Forum
💉 NKGen Receives FDA Approval for Expanded Access to Neurodegenerative Therapy
🧬 Cellular Therapy Developed for Cancer Now Tested in Autoimmune Disease
🇬🇧 UK Pioneers Bedside Production of Personalized Therapies
💡 NeuroScientific Biopharmaceuticals Expands Stem Cell Portfolio with Key Acquisition
🧪 Spliceor Receives UK Funding for Liver Cancer Gene Therapy Development
🧬 Yale Develops Novel Antibody-RNA Therapy for Resistant Cancers
This isn’t just a recap—it’s your weekly intelligence drop on the science transforming modern medicine. 🎯
📢 Stay Ahead in Gene and Cell Therapy Research!
✅ Like, share, and subscribe for weekly updates on gene therapy, cell therapy, rare diseases, and biotech innovation
#GeneTherapy #CellTherapy #CAR_T #NeurodegenerativeDiseases #GeneTherapyBreakthroughs #FDAApprovals #Immunotherapy #BiotechInnovation #LucidQuest #LQVentures #ClinicalTrials #BiotechNews #CAR_NK #StemCellTherapies